FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756288510> ?p ?o ?g. }

• W2756288510 abstract "Background Etanercept (ETN) is an established bDMARDs for therapy of rheumatoid arthritis and some other inflammatory diseases. In rheumatoid arthritis patients ETN could be given in combination therapy with sDMARDs as well as in monotherapy. Objectives To investigate and compare etanercept monotherapy versus combination with sDMARDs in RA patients regarding survival on drug, efficacy, quality of life and reason for discontinuation. Methods Observational, open, long-term study of patients from the ATTRA registry starting the ETN therapy since 2010 either on monotherapy or in combination with sDMARDs (n=605). 461 patients (80.7%) were females, rheumatoid factor was positive in 429 (76.6%), anti CCP antibodies in 412 (74.5%) patients. The following groups of patients were assessed: Etanercept monotherapy (ETN-mono, n=83), combination with methotrexate (Combo-MTX, n=378), combination with other sDMARDs (Combo-other sDMARDs, n=110). Mean ± SD and absolute/relative frequencies were used to describe continuous and categorical variables, respectively. P-value of Pearson Chi-square test and Kruskal-Wallis test is given when assessing differences between groups in categorical and continuous variables. Results are presented as hazard ratio (HR) with corresponding p-value. Statistical evaluation was processed by IBM SPSS Statistics ver. 24. Results In the first measurement of activity after 3 months, there were significantly lower disease activity in both Combo groups compared to ETN mono (3.2±0.1 resp. 2.9±0.1 versus 3.7±0.2, p The HAQ value was significantly higher already at the time of ETN onset at month 0 in the ETN-mono group (1.7 versus 1.4 resp. 1.5, p The hazard ratio (HR) for ETN discontinuation was higher in ETN mono group compared to Combo-MTX (HR=1.330) and also compared to Combo-other sDMARDs (HR=1.098), even if the differences did not reach statistical significance (p=0.131, resp. 0.671). Similar trend was evident, if the etanercept was given in the first and any subsequent line of biological therapy. The HR for ETN discontinuation was also numerically higher in Combo-other sDMARDs than in Combo MTX group (HR=1.211, p=0.244). The patients on ETN mono have higher risk of discontinuation due to inefficacy compared to Combo-MTX (HR=1.415) and also to Combo-other sDMARDs (HR=1.670). The patients of combo-other sDMARDs group had lower risk of discontinuation due to inefficacy also in comparison with combo-MTX (HR=0.847). None of the differences reach statistical significance. The patients on ETN mono have higher risk of discontinuation due to adverse event compared to Combo-MTX and also to Combo-other sDMARDs. This trend is higher, if ETN is given in the subsequent line of biological therapy, but not in first line. Nevertheless like in other situations, the differences showed some trend, but were not statistically significant. Conclusions Results support the evidence of advantages of ETN combination with methotrexate – quicker onset of efficacy and give some evidence of better survival on etanercept therapy in combination with methotrexate. Acknowledgements Supported by AZV 15–28659A Disclosure of Interest None declared" @default.
• W2756288510 created "2017-09-25" @default.
• W2756288510 creator A5003521221 @default.
• W2756288510 creator A5019487270 @default.
• W2756288510 creator A5029551154 @default.
• W2756288510 creator A5058608284 @default.
• W2756288510 creator A5079921904 @default.
• W2756288510 creator A5084684549 @default.
• W2756288510 creator A5089477356 @default.
• W2756288510 date "2017-06-01" @default.
• W2756288510 modified "2023-09-24" @default.
• W2756288510 title "AB0387 Comparison of etanercept in monotherapy and combination with synthetic dmards: data from attra registry" @default.
• W2756288510 doi "https://doi.org/10.1136/annrheumdis-2017-eular.2583" @default.
• W2756288510 hasPublicationYear "2017" @default.
• W2756288510 type Work @default.
• W2756288510 sameAs 2756288510 @default.
• W2756288510 citedByCount "0" @default.
• W2756288510 crossrefType "proceedings-article" @default.
• W2756288510 hasAuthorship W2756288510A5003521221 @default.
• W2756288510 hasAuthorship W2756288510A5019487270 @default.
• W2756288510 hasAuthorship W2756288510A5029551154 @default.
• W2756288510 hasAuthorship W2756288510A5058608284 @default.
• W2756288510 hasAuthorship W2756288510A5079921904 @default.
• W2756288510 hasAuthorship W2756288510A5084684549 @default.
• W2756288510 hasAuthorship W2756288510A5089477356 @default.
• W2756288510 hasBestOaLocation W27562885101 @default.
• W2756288510 hasConcept C126322002 @default.
• W2756288510 hasConcept C2776999253 @default.
• W2756288510 hasConcept C2777226972 @default.
• W2756288510 hasConcept C2777575956 @default.
• W2756288510 hasConcept C2778715236 @default.
• W2756288510 hasConcept C2780132546 @default.
• W2756288510 hasConcept C2781059491 @default.
• W2756288510 hasConcept C71924100 @default.
• W2756288510 hasConcept C90924648 @default.
• W2756288510 hasConceptScore W2756288510C126322002 @default.
• W2756288510 hasConceptScore W2756288510C2776999253 @default.
• W2756288510 hasConceptScore W2756288510C2777226972 @default.
• W2756288510 hasConceptScore W2756288510C2777575956 @default.
• W2756288510 hasConceptScore W2756288510C2778715236 @default.
• W2756288510 hasConceptScore W2756288510C2780132546 @default.
• W2756288510 hasConceptScore W2756288510C2781059491 @default.
• W2756288510 hasConceptScore W2756288510C71924100 @default.
• W2756288510 hasConceptScore W2756288510C90924648 @default.
• W2756288510 hasLocation W27562885101 @default.
• W2756288510 hasOpenAccess W2756288510 @default.
• W2756288510 hasPrimaryLocation W27562885101 @default.
• W2756288510 isParatext "false" @default.
• W2756288510 isRetracted "false" @default.
• W2756288510 magId "2756288510" @default.
• W2756288510 workType "article" @default.